Glaukos Corporation (GKOS)
GKOS moved a median of +0.04% 30 minutes after news, and +0.18% by the close. How GKOS actually reacts to news — the realized, point-in-time move the market made, measured across 452 labeled events over the last three years with zero look-ahead.
GKOS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 450 |
| 30-min | +0.04% | 51% | 451 |
| 60-min | +0.01% | 51% | 451 |
| to close | +0.18% | 54% | 448 |
| Middle 50% of GKOS reactions | -0.55% to +0.76% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 452 |
Half of all Glaukos Corporation news events land between -0.55% and +0.76% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GKOS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 29 | +0.14% | 52% | +0.17% |
| Analyst downgrades | 18 | +0.21% | 56% | +0.07% |
| Coverage initiations | 18 | +0.21% | 56% | -0.87% |
| Rating reiterations | 138 | -0.04% | 48% | -0.73% |
| Price-target raises | 48 | +0.05% | 52% | -0.92% |
| Price-target cuts | 12 | -0.13% | 50% | +0.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how GKOS ranks against every other measured name →
That’s how GKOS usually reacts — get an email when it moves on news →Email me when GKOS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GKOS's baseline. Nothing else.
Recent GKOS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery | Press release | Business Wire | +2.03% | +3.52% | |
| Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases | Press release | Business Wire | -1.06% | -5.45% | |
| Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus | Press release | Business Wire | -1.06% | -5.45% | |
| Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 | Press release | Business Wire | +6.03% | +6.94% | |
| Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus | Press release | Business Wire | +1.12% | -3.97% | |
| Glaukos Announces Participation in Wells Fargo Healthcare Conference | Press release | Business Wire | +0.69% | +1.91% | |
| Form 8-K GLAUKOS Corp For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +1.31% | |
| Form 10-Q GLAUKOS Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.95% | -5.82% | |
| Form 8-K GLAUKOS Corp For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -4.95% | -5.82% | |
| Glaukos Announces Second Quarter 2026 Financial Results | Press release | Business Wire | -4.95% | -5.82% | |
| Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt | Press release | Business Wire | -0.73% | -2.33% | |
| Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 | Press release | Business Wire | -0.54% | +1.04% | |
| Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis | Press release | Business Wire | +0.87% | +2.13% | |
| Form 8-K GLAUKOS Corp For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | +6.57% | |
| Form SD GLAUKOS Corp | SEC filing · Form SD | SEC EDGAR | -0.23% | -3.02% | |
| Glaukos Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | +0.53% | +0.93% | |
| Form 8-K GLAUKOS Corp For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | -2.74% | |
| Form 10-Q GLAUKOS Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.40% | +2.62% | |
| Form 8-K GLAUKOS Corp For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | +2.62% | |
| Glaukos Announces First Quarter 2026 Financial Results | Press release | Business Wire | -1.40% | +2.62% | |
| Form ARS GLAUKOS Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.33% | +0.41% | |
| Form DEF 14A GLAUKOS Corp For: May 28 | SEC filing · Form DEF | SEC EDGAR | -0.33% | +0.41% | |
| Form DEFA14A GLAUKOS Corp | SEC filing · Form DEFA14A | SEC EDGAR | -0.33% | +0.41% | |
| Glaukos Announces the Release of its 2025 Sustainability Report | Press release | Business Wire | -0.33% | +0.41% | |
| Glaukos Receives Permanent J-code for Epioxa™ | Press release | Business Wire | -0.33% | +0.41% | |
| Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 | Press release | Business Wire | +1.68% | -1.03% | |
| Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting | Press release | Business Wire | -0.26% | +3.95% | |
| Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care | Press release | Business Wire | -2.46% | -0.87% | |
| Form 8-K GLAUKOS Corp For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +1.75% | |
| Form S-8 GLAUKOS Corp | SEC filing · Form S-8 | SEC EDGAR | -0.41% | +0.66% | |
| Form 10-K GLAUKOS Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.74% | +1.08% | |
| Form 8-K GLAUKOS Corp For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +8.76% | +16.85% | |
| Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +8.76% | +16.85% | |
| Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR | Press release | Business Wire | +2.15% | +1.72% | |
| Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 | Press release | Business Wire | +0.03% | +4.12% | |
| Form 8-K GLAUKOS Corp For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | +9.93% | |
| Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance | Press release | Business Wire | -0.58% | +9.93% | |
| Glaukos Announces Participation in J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.26% | +1.97% | |
| Form 8-K GLAUKOS Corp For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +1.17% | +5.46% | |
| Glaukos Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | -0.42% | -0.80% | |
| Form 10-Q GLAUKOS Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.55% | +1.78% | |
| Form 8-K GLAUKOS Corp For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -7.96% | |
| Glaukos Announces Third Quarter 2025 Financial Results | Press release | Business Wire | -0.06% | -7.96% | |
| Glaukos Announces FDA Approval of Epioxa™ | Press release | Business Wire | -2.50% | -10.36% | |
| Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting | Press release | Business Wire | -0.40% | +2.52% | |
| Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 | Press release | Business Wire | -1.04% | +1.38% | |
| Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama | Press release | Business Wire | -0.80% | -1.85% | |
| Form S-8 GLAUKOS Corp | SEC filing · Form S-8 | SEC EDGAR | -0.02% | -0.09% | |
| Glaukos Announces Participation in Wells Fargo Healthcare Conference | Press release | Business Wire | +0.66% | +1.96% | |
| Form 8-K GLAUKOS Corp For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GKOS section they belong to.
Where else GKOS is measured.
GKOS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PROTEOSTASIS THERAPEUTICS (PTI) | 453 | -0.51% | 39% |
| TERRASCENT CORP (TRSSF) | 453 | -0.04% | 44% |
| Cosmos Health Inc. (COSM) | 450 | 0.00% | 50% |
| ROCHE HOLDING LTD S/ADR (RHHBY) | 449 | +0.03% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Glaukos Corporation's median reaction calculated?
Every labeled GKOS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 452 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of GKOS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GKOS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.